SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market.

On Tuesday, Vice Chancellor Morgan T. Zurn and U.S. District Judge Maryellen Noreika signed off on dismissal of a breach of contract case and an antitrust action, respectively, both of which Pfizer ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December ...

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...